Congenital mesoblastic nephroma

Summary

Congenital mesoblastic nephroma (MONDO:0017043) is a disease and 3 clinical trials. Molecularly, ETV6::NTRK3 Fusion confers sensitivity to Larotrectinib in Congenital Mesoblastic Nephroma (CIViC Level C). A subtype of mesoblastic nephroma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	congenital mesoblastic nephroma
Mondo ID	MONDO:0017043
Orphanet	2665
DOID	DOID:4773
ICD-11	2001572901
NCIT	C6569
UMLS	C1332965
MedGen	232058
GARD	0001493
MedDRA	10070665
Is cancer (heuristic)	no

Also known as: CMN · CMn · congenital mesoblastic nephroma · mesoblastic nephroma · stromal nephroma, malignant

Data availability: 1 cell line.

Disease family

This is a subtype of mesoblastic nephroma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant urinary system neoplasm › kidney cancer › mesoblastic nephroma › congenital mesoblastic nephroma

Subtypes (2): cellular congenital mesoblastic nephroma, classic congenital mesoblastic nephroma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02402244	Not specified	RECRUITING	Project: Every Child for Younger Patients With Cancer
NCT00898365	Not specified	COMPLETED	Study of Kidney Tumors in Younger Patients
NCT01642095	Not specified	WITHDRAWN	Studying Biomarkers in Samples From Younger Patients With Kidney Cancer

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items; also 5 diagnostic, 1 prognostic.

Molecular subtype	Therapy	Effect	Level	CIViC
ETV6::NTRK3 Fusion	Larotrectinib	Sensitivity/Response	CIViC C	EID10840